LAVA Therapeutics (NASDAQ:LVTX) Downgraded by Leerink Partnrs to Hold

Leerink Partnrs downgraded shares of LAVA Therapeutics (NASDAQ:LVTX) from a strong-buy rating to a hold rating in a report published on Thursday,Zacks.com reports.

A number of other research firms have also issued reports on LVTX. Leerink Partners restated a “market perform” rating and issued a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a report on Thursday. JMP Securities reissued a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research note on Wednesday. Finally, Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.67.

LAVA Therapeutics Stock Performance

LVTX stock opened at $1.20 on Thursday. The company’s 50 day simple moving average is $1.70 and its 200-day simple moving average is $1.84. LAVA Therapeutics has a 52-week low of $1.15 and a 52-week high of $6.47.

Hedge Funds Weigh In On LAVA Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in LAVA Therapeutics in the 3rd quarter worth about $32,000. XTX Topco Ltd bought a new stake in shares of LAVA Therapeutics in the 2nd quarter valued at approximately $55,000. Finally, Pathway Financial Advisors LLC grew its stake in shares of LAVA Therapeutics by 328.6% in the 2nd quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock valued at $108,000 after buying an additional 46,000 shares in the last quarter.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.